tirzepatide birth defects Ozempic and Pregnancy: Safety Concerns Explained Woman says she got pregnant

Do not use if you are pregnant, nursing or may become pregnant

Effects of oral contraceptives and hormone replacement therapy on markers of cobalamin status

Quality & Testing: How is sterility ensured for injectables

Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes